Timothy Miller, M.D., Ph.D. is the David Clayson Professor of Neurology at Washington University School of Medicine in St. Louis and serves as Vice-Chair of Research for the Department of Neurology.  His group focuses on developing novel therapies for neurodegenerative diseases, including ALS and tauopathies.  Dr. Miller has pioneered work with antisense oligonucleotides (ASOs) and has led successful ASO clinical trials in SOD1-related ALS and Alzheimer’s Disease, with clinical trials anticipated for other tauopathies.  His work received the Sheila Essey Award for ALS research in 2018, the Healey Center International Prize for Innovation in ALS in 2019, and the Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research in 2023.  Dr. Miller was elected to the National Academy of Medicine in 2023.

Dr. Miller holds bachelor’s degrees in Chemistry and French from the University of Virginia and a medical degree and PhD in Neuroscience from Washington University in St. Louis.  After residency and a fellowship program at the University of California, San Francisco, he completed a postdoctoral fellowship in the Clinical Scientist Training Program with Dr. Don Cleveland at the University of California, San Diego.  Upon completion of his postdoctoral work, Dr. Miller returned to Washington University in St. Louis where he opened the Miller Lab with a focus on developing methods to turn off harmful genes in the brain and spinal cord in order to treat neurodegenerative diseases.